Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.

@article{Gleixner2009TargetingOH,
  title={Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.},
  author={Karoline V. Gleixner and Matthias Mayerhofer and A. C. Vales and Alexander Gruze and Gregor Hoermann and Sabine Cerny-Reiterer and E. Lackner and Emir Hadzijusufovic and Harald Herrmann and Arun K Iyer and M. T. Krauth and Winfried F. Pickl and Brigitte Marian and Renate E Panzer-Gr{\"u}mayer and Christian Sillaber and Hiroshi Maeda and Christoph Zielinski and Peter Valent},
  journal={Current cancer drug targets},
  year={2009},
  volume={9 5},
  pages={675-89}
}
Heat shock protein 32 (Hsp32), also known as heme oxygenase-1 (HO-1), is a stress-related anti-apoptotic molecule, that has been implicated in enhanced survival of neoplastic cells and in drug-resistance. We here show that Hsp32 is expressed in most solid tumors and hematopoietic neoplasms and may be employed as a new therapeutic target as evidenced by experiments using specific siRNA and a Hsp32-targeting pharmacologic inhibitor. This Hsp-32 targeting drug, SMA-ZnPP, was found to inhibit the… CONTINUE READING